drugset / Trial / NCT00656812
Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
Phase 2
Completed
40 enrolled
Study Group of Medical Tumour Therapy (AGMT)
Hoffmann-La Roche · collabLipomed · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to evaluate whether a Rituximab plus 2 CdA combination therapy is effective and safe in the treatment of patients with advanced or relapsed lymphoma of the mucosa associated lymphoid tissue (MALT).
Timeline
- Start
- 2008-05
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cladribine | Small molecule | 0.1 mg/kg | Subcutaneous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |